1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
NATCO Pharma Limited

NATCO Pharma Limited

785.15
INR
+0.70
(+0.09%)
63.92EPS
14.46P/E
166.80BMarket Cap
Nov 17Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
45.83
49.43
62.38
114.51
121.63
111.93
103.76
92.79
104.45
147.73
221.67
246.31
225.81
194.57
Basic EPS, GAAP
6.43
8.13
9.22
27.89
39.26
34.98
25.33
24.2
9.32
39.18
77.34
105.26
79.2
63.89
Free Cash Flow per Basic Share
2.11
-1.6
-2.65
3.81
2.22
11.24
3.23
2.43
-10.76
35.25
47.52
66.17
76.89
- -
Dividend per Share
1.21
1.2
1.53
8.09
10.23
6.02
8.44
6.25
4.51
5.5
9.52
6.02
5.04
- -
Book Value per Share
43.9
50.83
74.39
94.62
166.52
190.92
207.26
226.04
233.6
267.1
326.79
424.71
514.83
- -
Tangible Book Value per Share
41.96
48.27
74.08
93.95
166.2
190.44
206.77
225.53
226.31
256.81
316.01
409.85
500.47
- -
Basic Weighted Avg Shares
160
166
170
174
177
184
182
182
182
183
179
179
179
179
Sales/Revenue/Turnover
7,321
8,186
10,633
19,951
21,567
20,618
18,878
16,903
19,049
26,969
39,788
44,116
40,445
34,846
Operating Margin (%)
20.57
20.94
21.72
32.86
40.59
34.82
26.02
29.66
7.39
29.3
39.63
44.91
31.06
24.56
Depreciation Expense
304
473
510
544
662
810
998
1,169
1,426
1,638
1,868
2,352
2,066
1,961
Net Income, GAAP
1,027
1,346
1,571
4,860
6,962
6,444
4,608
4,409
1,700
7,153
13,883
18,854
14,185
11,443
Effective Tax Rate (%)
23.93
2.94
23.77
22.34
21.64
22.11
19.45
23.67
15.92
17.01
17.04
17.81
7.98
8.21
Profit Margin (%)
14.03
16.44
14.77
24.36
32.28
31.25
24.41
26.08
8.92
26.52
34.89
42.74
35.07
32.84
Working Capital
559
738
3,439
4,608
15,387
16,185
16,403
18,192
17,763
23,172
30,507
43,265
33,714
- -
LT Debt
955
970
- -
- -
- -
- -
9
9
80
11
53
46
1,042
- -
Total Equity
7,328
8,496
13,006
16,534
30,760
34,910
37,847
41,234
42,636
48,738
58,531
76,123
92,211
- -
Return on Invested Capital (%)
12.28
14.17
13.06
29.58
26.6
15.93
10.12
9.37
3.04
13.6
23.09
23.95
12.67
- -
Return on Capital (%)
14.38
15.71
13.52
30.38
27.62
18.49
11.96
10.47
3.98
14.84
24.8
26.94
16.18
- -
Return on Common Equity (%)
16.31
17.14
14.68
33.01
29.49
19.64
12.69
11.17
4.05
15.66
25.88
28.01
16.86
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
6,097
- -
LT Borrowings
- -
1,000
- -
LT Finance Leases
- -
42
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
181
179
181
Market Capitalization
161,745
173,079
166,805

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
50,523
- -
Cash, Cash Equivalents & STI
- -
27,881
- -
Accounts Receivable, Net
- -
8,812
- -
Inventories
- -
9,085
- -
Total Current Liabilities
- -
16,809
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
6,097
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
23.3%
17.8%
21.13%
Free Cash Flow
-84.1%
-176.83%
16.2%
Net Income, GAAP
57.68%
72.89%
-24.76%
Sales/Revenue/Turnover
17.68%
20.87%
-8.32%
Total Cash Common Dividend
45.37%
2.24%
-16.33%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
13,626
13,711
4,748
12,210
44,116
2026
13,289
13,630
6,473
7,391
40,445
2027
7,352
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
37.32
37.81
7.43
22.7
105.26
2026
26.84
28.94
8.46
14.96
79.2
2027
11.53
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
6.02
2026
- -
- -
- -
- -
5.04
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Rajeev Nannapaneni
Full Time Employees
5,060
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Natco House Hyderabad TS India 500034
IPO Date
Jan 23, 1995
Website
natcopharma.co.in
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
NATCO Pharma Limited, headquartered in Hyderabad, India, and founded in 1981, develops, manufactures and markets finished dosage formulations, active pharmaceutical ingredients and agrochemicals, with a focus on generic oncology medicines; branded drugs in cardiology, diabetology, gastroenterology, neurology, infectious diseases including HIV and hepatitis C, orthopedics and rheumatology; and niche products such as chemotherapy agents, targeted therapies, antiviral medications, central nervous system treatments, cardiovascular drugs and biosimilars for cancer and autoimmune conditions. The company operates facilities in Telangana and Andhra Pradesh, supplies APIs to other pharmaceutical firms, provides contract manufacturing services and exports to over 50 countries spanning North America, Europe, Asia-Pacific and emerging markets. In 2025, NATCO completed its strategic acquisition of a 35.75% stake in South Africa's Adcock Ingram Holdings Limited for approximately Rs 2000 crore, marking entry into the African pharmaceutical market and leveraging the target's established presence for expanded revenue streams and regional growth; it also launched generic versions of complex blockbusters like Glatiramer Acetate for multiple sclerosis in the US and continues portfolio expansion in specialty formulations and crop health sciences with products such as chlorantraniliprole-based agrochemicals.